Drug Profile
Research programme: beta catenin inhibitors - Prolexys
Alternative Names: Pair 4 compound series; PRLX 43318 compound series; PRLX 8025; PRLX2113; PRXL 2113Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Prolexys Pharmaceuticals
- Class Small molecules
- Mechanism of Action Beta catenin inhibitors; Signal transduction pathway inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Colorectal cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Colorectal-cancer in USA
- 23 Aug 2006 This programme is still in active development for Colorectal cancer
- 25 Feb 2005 Preclinical trials in Colorectal cancer in USA (unspecified route)